FDA Approves Promising Alzheimer’s Treatment

Leading Florida Neurologists Available to Speak about Biogen Aducanumab Treatment

Alzheimer’s patients and their families, as well as the medical community, are celebrating today’s decision by the FDA to approve Biogen’s Aducanumab, a promising infusion treatment for Alzheimer’s patients.

Dr. Jeffrey Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, has been closely following the approval process and is thrilled about the outcome.

“For the past 18 years, we have been operating in a treatment desert,” he said. “This monthly infusion treatment will be a game-changer for patients who otherwise will simply end up in long-term care facilities. My colleagues and I are anxious to get started with the process of offering this hope to our patients across Florida.”

The treatment, which requires monthly infusions and extensive diagnostics to determine eligibility, must be administered at comprehensive neurology centers. First Choice Neurology physicians are located in more than 40 locations, including Miami-Dade, Broward, and Palm Beach Counties, as well as the Tampa Bay area in Central Florida.

The following Neurologists are experienced in the treatment of Alzheimer’s disease, knowledgeable about Aducanumab, and available for media interviews:

About First Choice Neurology:

As the largest private pediatric and adult neurology group in the United States, First Choice Neurology has more than 80 neurologists and 120 support healthcare staff members, operating out of 41 facilities in six Florida counties and in 35 major hospitals.

The Florida medical group of neurologists, nurse practitioners, physician assistants, neuropsychologists as well as occupational therapists (OTs), and physical therapists (PTs), began serving patients in 2004 in response to South Florida’s increasing need for high-quality neurology services. First Choice offers both diagnostic and physical rehabilitative services for patients with a wide variety of neurological conditions, including Alzheimer’s disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson’s disease, sleep disorders, and strokes. Additional subspecialties include neuromuscular disorders, neuro-ophthalmology, pain management, neuropsychology, neuroradiology, physical medicine, and rehabilitation.

For more information about First Choice Neurology, visit the website at https://www.fcneurology.net/

Visit us on Social Media
Facebook: https://www.facebook.com/FCNeurology/
Twitter: https://twitter.com/FCNeurology
LinkedIn: https://www.linkedin.com/company/first-choice-neurology
Instagram: https://www.instagram.com/firstchoiceneurology/
YouTube: https://www.youtube.com/channel/UCi8MbgW-hk2XyB6GLisvuMQ

Resource: FDA Accelerated Approval